Search Results
Your search for ,Per matches 3906 pages
Showing 601 - 650Impact of MCCPDC Prices of Generic Oncology Drugs on Medicare Beneficiaries
Medicare beneficiaries could save between $228.1 million and $2.15 billion per year if insurers operating the U.S. government's Medicare Part D plans purchased seven generic oncology drugs at the same prices obtained by the Mark Cuban Cost Plus Drug Company (MCCPDC), according to a new study...
Risk Factors for Primary Bone Cancer in Childhood Cancer Survivors: Bone Tissue Radiation Exposure and Alkylating Agent Dose
In a case-control study reported in the Journal of Clinical Oncology, Reulen et al found that an increased risk of primary bone cancer was associated with increasing radiation dose to bone tissue and increasing alkylating agent dose among survivors of childhood cancer. As noted by the...
Study Illuminates Potential Marked Disparities in Federal Cancer Research Funding
Investigators have found that federal cancer research funding tends to be allocated more heavily toward cancers that occur more often in non-Hispanic White patients than those that occur more frequently in other racial and ethnic groups, according to a new study published by Haghighat et al in the...
Fecal Microbiota Transplantation: Its Role for Patients Undergoing Allogeneic HCT and Receiving Induction Therapy for AML
In a single-institution phase II study reported in the Journal of Clinical Oncology, Rashidi et al found that fecal microbiota transplantation (FMT) did not reduce the risk of infection in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) or patients with acute myeloid...
Expert Point of View: Devraj Basu, MD, PhD, FACS
Devraj Basu, MD, PhD, FACS, of the Perelman School of Medicine, University of Pennsylvania, an expert in human papillomavirus (HPV)-related oropharyngeal cancer, commented on this study: “This abstract shows lack of awareness of multiple types of HPV-associated cancer and a reduced awareness of...
Toripalimab Plus Chemotherapy Improves Event-Free Survival in Resectable Stage III NSCLC
Findings from a phase III, randomized trial highlight the benefit derived from perioperative immunotherapy in patients with early-stage resectable non–small cell lung cancer (NSCLC), according to data presented during the ASCO Plenary Series: April 2023 Session.1 Interim analysis of the Neotorch...
Rethinking Prior Authorization
Prior authorization of medical procedures, services, and medications has been a standard requirement of health-care providers for decades. Rising health-care costs, specifically the escalating prices of cancer drug therapies, have led to a new focus by payers, providers, and policymakers on prior...
5α-Reductase Inhibitor Use and Progression of Bladder Cancer in South Korean Males
In a Korean cohort study reported in JAMA Network Open, An et al found that men with prescriptions for 5α-reductase inhibitors prior to diagnosis of urothelial bladder cancer had better outcomes than those with no prior prescriptions. Study Details The study analyzed patient claims data from the...
NCCN Addresses Ongoing Chemotherapy Shortages as New Survey Suggests More than 90% of Cancer Centers May Be Impacted
Results of a new survey from the National Comprehensive Cancer Network (NCCN) have shed light on the widespread impact of the current carboplatin and cisplatin shortages. In a separate statement, the NCCN called on the whole oncology community to work together on solutions. Background Carboplatin...
Microdoses of Incisional Antibiotics and Surgical Site Infections in Surgery for Skin Cancer
In a single-institution study conducted in New Zealand reported in JAMA Surgery, Goh et al found that microdoses of incisional antibiotics may reduce the risk of surgical site infections during surgery for skin cancer, as well as reduce the risk of infections requiring postoperative systemic...
Exercise May Strengthen Immune System in Patients With Multiple Myeloma
Researchers have found that exercise may be effective at strengthening the immune system in patients with multiple myeloma, providing them with a nonpharmaceutical method of managing the disease, according to new findings presented by Joseph et al at the 2023 ASCO Annual Meeting (Abstract 8060)....
FDA Approves Olaparib Plus Abiraterone and Prednisone or Prednisolone for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
On May 31, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) in combination with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, as determined by an...
SGLT2 Inhibitors and Cardiovascular Outcomes in Older, Anthracycline-Treated Patients With Cancer
In a population-based cohort study reported in JACC: CardioOncology, Abdel-Qadir et al found that receipt of sodium glucose cotransporter-2 (SGLT2) inhibitors was associated with a reduced risk of hospitalization for heart failure—but not risk for heart failure—among patients aged ≥ 65 years with...
CRISPR Approach May Help Identify Therapeutic Targets in Patients With Multiple Myeloma
Researchers have identified 116 genes as key molecular vulnerabilities for multiple myeloma, according to a novel study published by de Matos Simoes et al in Nature Cancer. The findings demonstrated the potential for these genes to act as leads and help researchers discover new therapeutic options...
Patients Who Practice Qigong May Be Able to Improve Their Cancer-Related Fatigue
Researchers have found that patients with cancer-related fatigue who practiced qigong may have demonstrated clinically significant improvements in their fatigue burden after 10 weeks, according to a new study published by Zimmerman et al in Integrative Cancer Therapies. The findings revealed that...
Addition of First-Line Dalpiciclib to Letrozole or Anastrozole in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
In an interim analysis of a Chinese phase III trial (DAWNA-2) reported in The Lancet Oncology, Zhang et al found that the addition of the CDK4/6 inhibitor dalpiciclib to letrozole or anastrozole improved progression-free survival as first-line treatment in patients with advanced hormone...
Tumor Genomic Profile and Risk for Arterial Thromboembolism in Patients With Solid Cancer
In a single-institution study reported in JACC: CardioOncology, Stephanie Feldman, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that somatic KRAS and STK11 alterations were associated with increased risk of arterial thromboembolism in patients with solid tumors,...
Surviving, but Not Always Thriving, After Cancer
As discussed in Part I of this special feature on cancer survivorship, there are now more than 18 million cancer survivors in the United States, and that number is expected to grow to 26 million by 2040.1 However, most of those survivors—at least two-thirds—either cured or in remission or living...
Surviving, but Not Always Thriving, After Cancer
The improvement in cancer survival rates since President Richard M. Nixon signed the National Cancer Act of 1971 into law is staggering. The legislation further committed the United States to greater investments in cancer-focused research to drive down the rates of cancer diagnoses, boost patient...
Radiation Oncology Workforce Expected to Remain Stable Through 2030
A new analysis of the U.S. radiation oncology workforce projects a relative balance between the supply of radiation oncologists and the demand for radiation therapy services through 2030.1 The report was produced by Health Management Associates (HMA), a consulting firm commissioned by the American...
Retifanlimab-dlwr for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma
On March 22, 2023, the anti–PD-1 antibody retifanlimab-dlwr was granted accelerated approval for adults with metastatic or recurrent locally advanced Merkel cell carcinoma.1 Supporting Efficacy Data Approval was based on findings in POD1UM-201 (ClinicalTrials.gov identifier NCT03599713), a...
SGO Presentations Explore Inequitable Access to Clinical Trials and Its Impact on Survival
Two studies presented at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer underscore the importance of enrolling patients with gynecologic cancer on clinical trials and of assuring trial access to racial minorities. One study found a statistically significant...
Genetic Sequencing May Identify Cancers Often Missed by Traditional Screening Guidelines
Whole-exome sequencing of a large database identified carriers of mutations associated with hereditary cancer syndromes (ie, hereditary breast and ovarian cancers and Lynch syndrome). What was surprising was that among those carriers, about 40% did not satisfy the existing National Comprehensive...
IMbrave050 Trial: Adjuvant Regimen of Atezolizumab Plus Bevacizumab in Resectable Hepatocellular Carcinoma
Adjuvant treatment with the combination of atezolizumab and bevacizumab achieved a statistically significant and clinically meaningful improvement in recurrence-free survival compared with active surveillance alone in patients with high-risk hepatocellular carcinoma following curative-intent...
BCG Vaccines May Provide Protective Effect Against Alzheimer's Disease
Researchers have found that patients treated with the Bacillus Calmette-Guérin (BCG) vaccine may have a reduced risk of Alzheimer’s disease and related dementias, according to a novel study published by Weinberg et al in JAMA Network Open. Background The BCG vaccine has been known to offer multiple ...
Late Major Surgical Intervention in Survivors of Childhood Cancer
In an analysis from the Childhood Cancer Survivor Study (CCSS) reported in The Lancet Oncology, Dieffenbach et al found that childhood cancer survivors had a heavy cumulative burden of late major surgical interventions. Study Details The study involved data from the CCSS on 5-year survivors of...
Exercise, Wellness Interventions in Early Breast Cancer Demonstrate Measurable Benefits—Even Economic Ones
Specialized exercise and wellness programs significantly elevated physical well-being and quality of life among patients with breast cancer while reducing the use of health-care resources in new research presented at the 2023 American Society of Breast Surgeons Annual Meeting. In one multicenter...
Implantable Ultrasound Device to Open Blood-Brain Barrier for Peritumoral Delivery of Albumin-Bound Paclitaxel in Recurrent Glioblastoma
In a small single-institution phase I trial reported in The Lancet Oncology, Sonabend et al found that an implantable device for low-intensity pulsed ultrasound with concomitant administration of intravenous microbubbles (LIPU-MB) may be safely used to open the blood-brain barrier to permit...
Immigrant Adults With Hepatocellular Carcinoma May Have Higher Survival Rates Than Those Born in the United States
Immigrant adult patients who have hepatocellular carcinoma and reside in the United States may have higher rates of survival compared with those who have the disease and were born in the United States, according to a new study published by Zhou et al in the Journal of the National Cancer Institute. ...
Adding Azacitidine to Standard Chemotherapy May Be Effective for Patients With PTCL-TFH
Researchers have found that azacitidine may be capable of increasing the effectiveness of chemotherapy and aiding nearly 90% of patients who had peripheral T-cell lymphoma with the T follicular helper cell phenotype (PTCL-TFH) achieve remission, according to a novel study published by Ruan et al in ...
Ibrutinib and Rituximab vs Fludarabine, Cyclophosphamide, and Rituximab in Previously Untreated Patients With CLL
As reported in The Lancet Oncology by Peter Hillmen, MBChB, PhD, and colleagues, an interim analysis of the UK phase III FLAIR trial has shown significantly improved progression-free survival with ibrutinib and rituximab vs fludarabine, cyclophosphamide, and rituximab (FCR) in previously untreated...
Abiraterone Acetate Plus Prednisolone With or Without Enzalutamide in Patients With Metastatic Prostate Cancer Initiating ADT
In an analysis of the final results of two STAMPEDE platform phase III trials reported in The Lancet Oncology, Gerhardt Attard, PhD, and colleagues found that the addition of enzalutamide to abiraterone plus prednisolone did not appear to improve survival outcomes and was associated with worse...
SGO Presentations Explore Inequitable Access to Clinical Trials and Its Impact on Survival
Two studies presented at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer underscore the importance of enrolling patients with gynecologic cancer on clinical trials and of assuring trial access to racial minorities. One study found a statistically significant...
Lung Cancer Screening and Possible Unappreciated Benefits
Screening that reduces cancer mortality serves as a foundational element of impactful care for certain cancers. That said, harms related to screening deserve our attention—overdiagnoses; diagnostic odysseys that may be invasive, expensive, or even unintentionally harmful; overtreatment of diagnosed ...
Induction Failure in Pediatric and Young Adult Patients With T-Cell ALL
In an analysis reported in the Journal of Clinical Oncology, O’Connor et al found that pediatric and young adult patients with T-cell acute lymphoblastic leukemia (T-ALL) who did not respond to induction therapy had poorer outcomes vs those with induction response. The investigators also attempted...
Risk of Early-Onset Digestive Tract Cancers Among Young Adults With Nonalcoholic Fatty Liver Disease
In a Korean nationwide cohort study reported in the Journal of Clinical Oncology, Park et al found that individuals aged 20 to 39 years with nonalcoholic fatty liver disease (NAFLD) were at an increased risk of developing early-onset digestive tract cancers. Study Details The study included data on ...
Limited Surgery Plus Proton Therapy in Pediatric and Adolescent Patients With Craniopharyngioma
In a phase II trial (RT2CR) reported in The Lancet Oncology, Thomas E. Merchant, DO, and colleagues found that limited surgery plus proton therapy was associated with a high rate of disease control and a low rate of severe complications in pediatric and adolescent patients with craniopharyngioma....
Addition of Blinatumomab to Chemotherapy in Infant Patients With KMT2A-Rearranged ALL
In a phase II trial reported in The New England Journal of Medicine, van der Sluis et al found that the addition of blinatumomab—a bispecific T-cell engager molecule targeting CD19—to standard chemotherapy appeared to result in marked improvements in outcome among infants with KMT2A-rearranged...
Despite Gender-Affirming Surgery, Transgender Women May Still Be at Risk of Developing Prostate Cancer
Researchers have estimated that about 14 of every 10,000 transgender women may be at risk of developing prostate cancer, according to a new study published by Nik-Ahd et al in JAMA. Background Transgender women keep their prostates even after gender-affirming surgery, but the extent to which they...
Remote Outreach May Increase Uptake of and Adherence to Cancer Screenings in Females in Rural Settings
Females in rural areas may be six times more likely to receive timely breast, cervical, and colorectal cancer screenings with remote outreach that involves interactive education and follow-up support by telephone compared with females in rural areas who don’t have remote outreach, according to a...
Addition of Quizartinib to Chemotherapy in Newly Diagnosed FLT3-ITD–Positive Acute Myeloid Leukemia
As reported in The Lancet by Erba et al, the phase III QuANTUM-First trial has shown prolonged overall survival with the addition of the FLT3 inhibitor quizartinib to chemotherapy in patients with newly diagnosed FLT3-internal-tandem-duplication (ITD)-positive acute myeloid leukemia (AML). Study...
Meta-Analysis of Outcomes With Anthracycline-Containing and Taxane-Containing Chemotherapy in Early-Stage Breast Cancer
As reported in The Lancet by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), a patient-level meta-analysis showed that anthracycline/taxane regimens were associated with better outcomes compared with regimens excluding either drug class in patients with early-stage operable breast...
In BRCA-Mutated Ovarian Cancer, Neoadjuvant Olaparib Feasible, Appears Effective in Pilot Study
Encouraging outcomes were achieved in patients with BRCA-mutated ovarian cancer who received neoadjuvant treatment with olaparib in a feasibility study led by Shannon N. Westin, MD, MPH, Professor in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD...
Trastuzumab Deruxtecan vs Physician’s Choice in HER2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine
As reported in The Lancet by André et al, the phase III DESTINY-Breast02 trial has shown improved progression-free survival with fam-trastuzumab deruxtecan-nxki vs physician’s choice of treatment in patients with HER2-positive metastatic breast cancer who had received prior ado-trastuzumab...
Vitamin D Deficiencies May Lead to Health Disparities in Black Patients With Prostate Cancer
Investigators have found that vitamin D deficiencies may contribute to more aggressive prostate cancer in Black patients at a younger age compared with White patients, according to a new study published by Siddappa et al in Cancer Research Communications. The new findings could pave the way for...
Neoadjuvant Trabectedin and Radiotherapy in Myxoid Liposarcoma
In the phase II TRASTS study reported in JAMA Oncology, Sanfilippo et al found that neoadjuvant trabectedin and radiotherapy did not meet the target objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) in patients with myxoid liposarcoma but did exhibit activity...
Toripalimab Plus Chemotherapy May Improve Event-Free Survival in Resectable Stage III NSCLC
An interim analysis of the Neotorch study highlighted the potential of immunotherapy for the treatment of early-stage non–small cell lung cancer (NSCLC), according to data presented by Lu et al during the ASCO Plenary Series: April 2023 Session (Abstract 425126). The findings showed a significant...
Locally Advanced High-Risk Prostate Cancer
This is Part 3 of Novel Hormonal Therapies for Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alicia K. Morgans, Neeraj Agarwal, and David VanderWeele discuss the management of locally advanced high-risk...
Tumor Genomic Profile and Risk for Arterial Thromboembolism in Patients With Solid Cancers
In a single-institution study reported in JACC: CardioOncology, Feldman et al found that somatic KRAS and STK11 alterations were associated with increased risk of arterial thromboembolism in patients with solid tumors, irrespective of tumor type. Study Details The retrospective cohort study used...
Whole-Exome Sequencing May Help Identify Individuals With Cancer Predisposition Syndromes Missed by Current Screening Guidelines
Researchers revealed that 39.2% of patients who consented to whole-exome sequencing and were identified as carriers of predisposition genes for hereditary breast and ovarian cancer or Lynch syndrome did not qualify for genetic screening under current guidelines, according to new findings presented...
